Clinical trials: Heroin
Drug Dependence
Oxytocin and Cognitive Behavioral Therapy in Drug Dependence
Background: The therapeutic alliance between therapist and patient may contribute to favorable outcomes in all types of psychotherapy, including cognitive behavioral therapy (CBT) for drug dependence.
- Trial name
- NCT00975416
- Testing
- Cognitive Behavioral Therapy, Intranasal Oxytocin
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Opioid Use Disorder, Substance Use Disorder
Neurofeedback During Naturalistic Stimuli to Reduce Craving in Heroin Addiction
Support groups are an important component of addiction treatment, where individuals at more stable stages of their recovery help others by sharing personal experiences.
- Conditions
- Opioid Use Disorder, Substance Use Disorder, Heroin Use Disorder
- Trial name
- NCT07344233
- Testing
- Real-time fMRI Neurofeedback
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Opioid-Related Disorders, Heroin Dependence
Combining Neuro-Imaging and Non-Invasive Brain Stimulation for Clinical Intervention in Opioid Use Disorder
The overarching goal of this project is to expand the traditional expertise in non-invasive neuromodulation at the University of Minnesota towards developing novel paired-neuromodulation approaches using transcrancial direct…
- Conditions
- Opioid-Related Disorders, Heroin Dependence, Morphine Dependence
- Trial name
- NCT04495673
- Testing
- Transcranial Direct Current Stimulation (tDCS), Cognitive Training
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Minnesota
Opiate Dependence, Heroin Dependence
Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone
In pilot study now proposed, we plan to randomly assign 60 opioid dependent patients to the new model, Depot-BNT, or to BNT plus oral naltrexone for a 6-month trial.
- Trial name
- Depot-BNT (NCT00577408)
- Testing
- depot naltrexone, Oral Naltrexone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- New York State Psychiatric Institute
Heroin Dependence, Nicotine Dependence
Pioglitazone for Heroin and for Nicotine Dependence
The goal of the proposed research is to improve the effectiveness of treatments for opioid and for nicotine dependence by testing a novel pharmacological strategy.
- Trial name
- NCT01395797
- Testing
- PIO
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Heroin Dependence, Opioid-Related Disorders
Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry
The purpose of this study is to compare the effectiveness of extended-release naltrexone (XR-NTX) vs. enhanced treatment-as-usual (TAU) among opioid dependent adults leaving NYC jails.
- Trial name
- XOR (NCT01999946)
- Testing
- Extended-Release Naltrexone
- Where
- 2 sites in United States
- Volunteers
- 217 people
- Sponsor
- NYU Langone Health
Heroin Dependence
Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone
The study is designed to compare the abuse liabilities of intranasal buprenorphine and buprenorphine/naloxone in individuals who are physically dependent on sublingual buprenorphine.
- Trial name
- NCT01760473
- Testing
- Intranasal challenge drug
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Opioid-Related Disorders
Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal
Repeated use and/or abuse of opioid medications is generally associated with a characteristic withdrawal syndrome that develops after cessation of drug administration.
- Trial name
- AV411 (NCT00723177)
- Testing
- AV411
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Opiate Dependence
ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence
This is a Phase 3 multi-center trial designed to evaluate the clinical efficacy and safety of VIVITROL® (Medisorb® naltrexone 380 mg) versus placebo when administered to adults upon discharge from inpatient treatment for opioid…
- Trial name
- NCT00678418
- Testing
- VIVITROL® 380 mg
- Where
- Russia
- Volunteers
- 250 people
- Sponsor
- Alkermes, Inc.
Heroin Addiction
Buprenorphine for Prisoners
This five-year study examines the effectiveness of buprenorphine treatment provided to previously-addicted inmates(N=320; 160 males, 160 females) initiated in prison and continued in the community.
- Trial name
- NCT00574067
- Testing
- Buprenorphine +OTP, Buprenorphine +CHC, Counseling +OTP
- Where
- 2 sites in United States
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- Friends Research Institute, Inc.
Opioid Use Disorder
Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)
This study will evaluate the safety, effectiveness and tolerance of low doses of oral naltrexone along with buprenorphine to treat opioid use disorder prior to the first injection of VIVITROL.
- Trial name
- NCT02537574
- Testing
- NTX/BUP, NTX/PBO-B, PBO-N/PBO-B
- Where
- 20 sites in United States
- Volunteers
- 380 people
- Sponsor
- Alkermes, Inc.
Opioid Use Disorder, Stimulant Use Disorder
Suvorexant for Opioid/Stimulant Co-use
This study will evaluate whether Suvorexant 20mg reduces drug use and craving, and improves sleep and stress among persons with co-occurring opioid use disorder and stimulant use disorder.
- Trial name
- NCT05546515
- Testing
- Suvorexant (dual orexin receptor antagonist)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
Schizophrenia, Schizoaffective Disorder
Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder
The proposed study is a 4-site, 12-week, novel, feasibility, investigation of patients who have co-occurring diagnoses of schizophrenia and current substance use disorder (alcohol, cocaine, heroin, or cannabis).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Substance Use Disorders
- Trial name
- NCT03526354
- Testing
- Brexpiprazole, Treatment as Usual
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Massachusetts, Worcester
Cocaine-Related Disorders, Heroin Dependence
Employment-based Reinforcement of Naltrexone Ingestion and Abstinence
A randomized study is planned over 5 years to evaluate the effectiveness of the Therapeutic Workplace in promoting naltrexone ingestion and abstinence in unemployed opiate-dependent injection drug users.
- Conditions
- Cocaine-Related Disorders, Heroin Dependence, Opioid-Related Disorders, Substance Abuse, Intravenous
- Trial name
- NCT00149669
- Testing
- employment-based reinforcement
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Johns Hopkins University
Heroin Dependence, Opioid-Related Disorders
Addiction Treatment in Russia: Oral vs. Naltrexone Implant
Heroin addiction is a growing problem in Russia; individuals who enter heroin addiction treatment often relapse. Therefore, effective heroin addiction treatments are necessary to prevent relapse.
- Trial name
- NCT00218426
- Testing
- naltrexone implant, oral naltrexone
- Where
- 2 sites in United States, Russia
- Volunteers
- 306 people
- Sponsor
- University of Pennsylvania
Heroin Dependence
Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals
A short-term treatment with buprenorphine prior to initiating treatment with naltrexone may increase the proportion of heroin-dependent patients successfully inducted onto Vivitrol.
- Trial name
- NCT03711318
- Testing
- Buprenorphine/naloxone
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Cocaine-Related Disorders, Opioid-Related Disorders
The Therapeutic Workplace Initiation Study
The primary purpose of the study is to determine if the central feature of the Therapeutic Workplace, the abstinence reinforcement contingency, is critical to initiate cocaine abstinence in injection drug using methadone patients…
- Conditions
- Cocaine-Related Disorders, Opioid-Related Disorders, Heroin Dependence, Substance Abuse, Intravenous
- Trial name
- NCT00249470
- Testing
- Abstinence & Work, Work Only
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- Johns Hopkins University
Opiate Addiction
Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans
Despite the current available therapies for opioid-dependent patients, most patients relapse. This research project focuses on the development of a novel compound, cannabidiol, to modulate opioid craving in humans based on animal…
- Trial name
- NCT02539823
- Testing
- CBD 400 mg, CBD 800 mg
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Hurd,Yasmin, Ph.D.
Opioid-Related Disorders, Heroin Dependence
Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial
The study will assess the effectiveness of at-home vs. in-office induction for patients entering buprenorphine maintenance at Associates in Internal Medicine (AIM) primary care clinic.
- Trial name
- NCT00684554
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- New York State Psychiatric Institute
Opioid Dependence, Heroin Dependence
Memantine as a Supplement to Naltrexone in Treating Heroin Dependence
Prospective participants will undergo a screening process at the clinic to determine eligibility. After screening, eligible patients will complete an 8-day inpatient detoxification, followed by a 12-week outpatient phase.
- Trial name
- NAMHS (NCT00476242)
- Testing
- Vivitrol, memantine
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- New York State Psychiatric Institute